Vectura has made three appointments to its business development team as part of its efforts to enhance its position as an inhalation specialist in the pharmaceutical services space.
 
Trevor Archbold and Robert Gurley have been appointed as Business Development Directors, and will have territorial responsibility for Europe and the U.S. West Coast respectively. Additionally, Chris Vernall will join Vectura in August as Business Development Director, and will work with Mr. Archbold in Europe. All three will report to Mark Bridgewater, Vectura’s Chief Commercial Officer in March 2020.
 

Most recently, Mr. Archbold was Strategic Account Manager at DuPont Pharma Solutions, assisting a number of major pharma companies covering APIs and active/functional excipients, primarily for oral solid dose applications. He also held business development roles at The Dow Chemical Company, Croda and Catalent.




Mr. Gurley joins the company from Cambrex, where he was Director of Business Development for the North West territory. He has more than 20 years of CDMO experience
 




Mr. Vernall joins the company from Nanopharm (part of Aptar Pharma), a contract product development company for respiratory drug products, where he led its business development. He also served as senior analyst and Business Development Director at Intertek Melbourn.